From the Medicines Patent Pool, Geneva, Switzerland.
Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand.
Pediatr Infect Dis J. 2022 Jan 1;41(1):e1-e5. doi: 10.1097/INF.0000000000003331.
Children, although at lower risk of poor outcomes from COVID-19 relative to adults, still stand to benefit from therapeutic interventions. Understanding of COVID-19 clinical presentation and prognosis in children is essential to optimize therapeutic trials design. This perspective illustrates how to collectively accelerate pediatric COVID-19 therapeutic research and development, based on the experience of the Global Accelerator for Paediatric Formulations.
儿童感染 COVID-19 的不良结局风险相对成人较低，但仍可从治疗干预中获益。了解儿童 COVID-19 的临床表现和预后对于优化治疗试验设计至关重要。本观点基于全球儿科配方药物加速开发组织的经验，阐述了如何共同加速儿科 COVID-19 治疗的研究和开发。
